Renata Sano

ORCID: 0009-0002-0161-1797
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chronic Lymphocytic Leukemia Research
  • Monoclonal and Polyclonal Antibodies Research
  • CAR-T cell therapy research
  • Lysosomal Storage Disorders Research
  • Pharmacological Effects of Medicinal Plants
  • Natural product bioactivities and synthesis
  • Endoplasmic Reticulum Stress and Disease
  • Autophagy in Disease and Therapy
  • Cellular transport and secretion
  • Glycosylation and Glycoproteins Research
  • PI3K/AKT/mTOR signaling in cancer
  • Lymphoma Diagnosis and Treatment
  • Sphingolipid Metabolism and Signaling
  • Protein Kinase Regulation and GTPase Signaling
  • Pancreatitis Pathology and Treatment
  • ATP Synthase and ATPases Research
  • Virus-based gene therapy research
  • Heat shock proteins research
  • Advanced Materials and Mechanics
  • Cytokine Signaling Pathways and Interactions
  • Erythrocyte Function and Pathophysiology
  • Macrophage Migration Inhibitory Factor
  • Plant biochemistry and biosynthesis
  • Cellular Mechanics and Interactions
  • Nuclear Receptors and Signaling

Sanford Burnham Prebys Medical Discovery Institute
2011-2023

Pharmacyclics (United States)
2023

AbbVie (United States)
2023

Discovery Institute
2016

Vellore Institute of Technology University
2011

Indian Institute of Science Bangalore
2011

Hospital de Clínicas de Porto Alegre
2005-2011

St. Jude Children's Research Hospital
2004-2009

Universidade Federal do Rio Grande do Sul
2005-2008

Autophagy is a lysosomal degradation pathway that converts macromolecules into substrates for energy production during nutrient-scarce conditions such as those encountered in tumor microenvironments. Constitutive mitochondrial uptake of endoplasmic reticulum (ER) Ca 2+ mediated by inositol triphosphate receptors (IP 3 Rs) maintains cellular bioenergetics, thus suppressing autophagy. We show the ER membrane protein Bax inhibitor-1 (BI-1) promotes autophagy an IP R-dependent manner. By...

10.1101/gad.184325.111 article EN Genes & Development 2012-05-15

Autophagy is an evolutionarily conserved process for catabolizing damaged proteins and organelles in a lysosome-dependent manner. Dysregulation of autophagy may cause various diseases, such as cancer neurodegeneration. However, the relevance to diseases remains controversial because limited availability chemical modulators. Herein, authors developed fluorescence-based assay measuring activity protease, autophagin-1(Atg4B). The employs novel reporter substrate Atg4B composed natural (LC3B)...

10.1177/1087057110392996 article EN cc-by-nc-nd SLAS DISCOVERY 2011-01-19

Abstract Small molecule inhibitors of Bruton's tyrosine kinase (BTK) have been approved for the treatment multiple B-cell malignancies and are being evaluated autoimmune inflammatory diseases. Various BTK (BTKi) distinct potencies, selectivity profiles, binding modes within ATP-binding site. On basis latter feature, BTKis can be classified into those that occupy back-pocket, H3 pocket, hinge region only. Hypothesizing differing may differential impact on receptor (BCR) signaling pathway, we...

10.1158/1535-7163.mct-22-0642 article EN cc-by-nc-nd Molecular Cancer Therapeutics 2023-09-21

Endoplasmic reticulum (ER) stress occurs when unfolded proteins accumulate in the lumen of organelle, triggering signal transduction events that contribute either to cellular adaptation and recovery or alternatively dysfunction death. ER has been implicated numerous diseases. To identify novel modulators stress, we undertook a siRNA library screen kinome, revealing Interleukin-1 Receptor-Associated Kinase-2 (IRAK2) as contributor protein response (UPR) signaling stress-induced cell Knocking...

10.1371/journal.pone.0064256 article EN cc-by PLoS ONE 2013-05-28

Infantile GM1 gangliosidosis is caused by the absence or reduction of lysosomal beta-galactosidase activity. Studies conducted in Brazil have indicated that it one most frequent storage disorders southern part country. To assess incidence this disorder, 390 blood donors were tested for presence two common mutations (1622-1627insG and R59H) GLB1 gene. Another group, consisting 26 patients, polymorphisms (R521C S532G), an attempt to elucidate whether there a founder effect. The frequencies...

10.1590/s1415-47572011000100009 article EN cc-by Genetics and Molecular Biology 2011-01-01

We explored the effect of a novel synthetic triterpenoid compound cyano enone methyl boswellates (CEMB) on various prostate cancer and glioma cell lines. CEMB displayed concentration-dependent cytotoxic activity with submicromolar lethal dose 50% (LD(50)) values in 10 tumor lines tested. CEMB-induced cytotoxicity is accompanied by activation downstream effector caspases (caspases 3 7) upstream initiator involved both extrinsic (caspase 8) intrinsic 9) apoptotic pathways. By using short...

10.1158/1535-7163.mct-10-0887 article EN Molecular Cancer Therapeutics 2011-07-12

<div>Abstract<p>Small molecule inhibitors of Bruton's tyrosine kinase (BTK) have been approved for the treatment multiple B-cell malignancies and are being evaluated autoimmune inflammatory diseases. Various BTK (BTKi) distinct potencies, selectivity profiles, binding modes within ATP-binding site. On basis latter feature, BTKis can be classified into those that occupy back-pocket, H3 pocket, hinge region only. Hypothesizing differing may differential impact on receptor (BCR)...

10.1158/1535-7163.c.7005673.v1 preprint EN 2024-01-03

GM1 gangliosidosis is an autosomal recessive disorder caused by the deficiency of lysosomal acid hydrolase beta-galactosidase (beta-Gal). It one most frequent storage disorders in Brazil, with estimated frequency 1:17,000. The enzyme secreted and can be captured deficient cells targeted to lysosomes. There no effective treatment for gangliosidosis. To determine efficiency expression vector correcting genetic defect gangliosidosis, we tested transfer beta-Gal gene (Glb1) fibroblasts culture...

10.1590/s0100-879x2008000400005 article EN cc-by Brazilian Journal of Medical and Biological Research 2008-04-01

<div>Abstract<p>Small molecule inhibitors of Bruton's tyrosine kinase (BTK) have been approved for the treatment multiple B-cell malignancies and are being evaluated autoimmune inflammatory diseases. Various BTK (BTKi) distinct potencies, selectivity profiles, binding modes within ATP-binding site. On basis latter feature, BTKis can be classified into those that occupy back-pocket, H3 pocket, hinge region only. Hypothesizing differing may differential impact on receptor (BCR)...

10.1158/1535-7163.c.7005673 preprint EN 2024-01-03
Coming Soon ...